Navigation Links
Ophthalmic Pharmaceutical Drugs - Global Strategic Business Report

DUBLIN, Dec. 22, 2013 /PRNewswire/ -- Research and Markets ( has announced the addition of the "Ophthalmic Pharmaceutical Drugs - Global Strategic Business Report" report to their offering.


Ophthalmic pharmaceutical drugs is a uniquely competitive market kept perennially vibrant by refining technological changes in drug formulations and efficacy. Conventional drug delivery techniques are giving way to newer, and more effective therapies such as infusion-type medicines, slow-release delivery systems, and implantables.

The global market for ophthalmic drugs is witnessing substantial growth, due primarily to factors such as rising incidence as well as prevalence of eye disorders such as macular degeneration, diabetic retinopathy and presbyopia among the elderly population. Growth is also driven by the evolution of treatment options for age-macular degeneration, as well as the ensuing commercial and therapeutic success of Lucentis, which made the market more lucrative and a potential growth sector.

Conversely, the market is fraught with challenges, including absence of health insurance among the ageing population in developing countries. Meanwhile, low awareness related to ophthalmic disorders, primarily due to little or no awareness in rural areas, pose tremendous challenges for ophthalmic drugs market in developing countries.

The global ophthalmic drug market is likely to face a patent cliff after 2010 as patents of major products within ocular anti-allergic, anti-glaucoma, as well as anti-inflammatory/anti-inflective therapies expire. The market expansion and the development of ophthalmic franchises of major pharmaceutical providers would be hit by the ensuing generic incursion, along with the rising regulatory priorities with regards to the global healthcare reforms.

Though the high efficacy of Allegan/Inspire's Restasis and Roche/Genetech's Lucentis is likely to lead the markets for treatment of dry eye and wet Age-Macular Degeneration, respectively, the global ophthalmology treatment sales are expected to stay more or less flat during the ensuing years.

Key Topics Covered:

1. Introduction, Methodology & Product Definitions

2. Industry Overview

3. Market Dynamics

4. An Overview Of Ophthalmic Drugs

5. Ophthalmic Disorders: A Freeze Frame

6. Fda Approvals And Product Launches

7. Fda Approvals And Product Approvals Launches In The Recent Past - A Perspective Builder

8. Recent Industry Activity

9. Corporate Activity In Recent Past - A Perspective Builder

10. Focus On Select Global Players

11. Global Market Perspective

12. The United States

13. Canada

14. Japan

15. Europe

16. Asia-Pacific

17. Latin America

18. Rest Of World

Companies Mentioned:

  • Aurolab (India)
  • Bohus Biotech AB (Sweden)
  • Cynacon/OCuSOFT (USA)
  • E Fougera & co (USA)
  • Farmak PubJSC (Ukraine)
  • Farmigea SpA (Italy)
  • GSK Consumer Healthcare (Malaysia)
  • GenVec, Inc (USA)
  • Genaera Corporation (USA)
  • Gland Pharma Ltd (India)
  • Hemomont doo (Serbia and Montenegro)
  • Hi-Tech Pharmacal Co, Inc (USA)
  • ISTA Pharmaceuticals (USA)
  • Indkus Drugs And Pharma Pvt, Ltd (India)
  • Insite Vision, Inc (USA)
  • Inspire Pharmaceuticals, Inc (USA)
  • Laboratório Edol Produtos Farmacêuticos, SA (Portugal)
  • Miravant Medical Technology (USA)
  • NPS Pharmaceuticals (USA)
  • Nascent Pharmaceuticals, Inc (USA)
  • Novagali Pharma SA (France):
  • Novartis AG (Switzerland)
  • OSI Pharmaceuticals (USA)
  • Othera Pharmaceuticals (USA)
  • Otsuka Pharmaceutical (Japan)
  • Oxigene, Inc (USA)
  • Pfizer, Inc (USA)
  • QLT, Inc (Canada)
  • Rohto Pharmaceutical Company Ltd (Japan)
  • Sucampo Pharmaceuticals, Inc (USA)
  • Unimed Pharma Sro (Slovakia)
  • Ursapharm Arzneimittel GmbH & Co, KG (Germany)
  • Vitamed Pharmaceutical Industries Ltd (Israel)

For more information visit

Media Contact:

Laura Wood , +353-1-481-1716,

SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Shire Reports Top-Line Results on OPUS-2, a Phase 3 Study Investigating the Use of Lifitegrast (5.0% Ophthalmic Solution) in Adults With Dry Eye Disease
2. Ophthalmic Instrumentation - Global Strategic Business Report - 2012 Featuring Abbott, Bausch & Lomb, Carl Zeiss and Others
3. VisionCare Ophthalmic Technologies Secures Up To $15MM To Accelerate Growth Of Its Novel Treatment For Age-Related Macular Degeneration
4. JHP Pharmaceuticals Enters Agreement to Produce Unique Late Stage Ophthalmic Product
5. Altaire Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of 9 lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution sold under several brands
6. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
7. Ohr Pharmaceutical Announces Addition of Dr. John Wroblewski to Ophthalmic Scientific Advisory Board
8. Key Findings: Innovations in Ophthalmic Devices - Anterior Segment
9. Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million
10. Sony Announces First East and West Coast Installations of 3D Imaging Solution for Ophthalmic Surgery
11. Brazil Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
Post Your Comments:
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):